Expression of ergotope-associated markers of T lymphocytes in atopic dermatitis after in vitro polyclonal activation
- Authors: Blinova E.A.1, Pashkina E.A.1, Tevs A.E.2,3, Nepomnyashchikh V.M.2, Leonova M.I.2, Demina D.V.2, Kozlov V.A.1,3
-
Affiliations:
- Institute of Fundamental and Clinical Immunology
- Clinic of Immunopathology
- Chair of Clinical Immunology
- Issue: Vol 11, No 6 (2017)
- Pages: 434-439
- Section: Article
- URL: https://journals.rcsi.science/1990-519X/article/view/212489
- DOI: https://doi.org/10.1134/S1990519X17060025
- ID: 212489
Cite item
Abstract
The antiergotypic response leads to the formation of effector T cells able to eliminate activated lymphocytes independently of their antigenic specificity, since the targets of these cells are molecules produced during cell activation (ergotopes). In this paper, we describe the level of expression of the ergotope-associated markers CD25, HSP60, and HLA-DR by the T lymphocytes isolated from the blood of atopic dermatitis patients immediately after isolation and after cultivation. After 10-day cultivation in the presence of anti-CD3 antibodies and IL-2, the expression levels of early and late activation markers in T cells have changed: the shares of CD25-positive CD4+ and CD8+ lymphocytes increase to 68 and 47%, respectively, and the share of HLA-DR-positive cells increases to 26 and 33%. The density of HLA-DR molecules on the surface of activated T cells increases more than fivefold. Almost all T cells before and after cultivation express 60 kDa heatshock protein (HSP60); however, the CD4+ cells activated in vitro contain more HSP60 molecules than do the in vitro-activated CD8+ cells and the CD4+ cells of peripheral blood. Thus, the T cells of atopic-dermatitis patients have the status of activated cells because they express sufficient amounts of early and late activation markers; presumably, they can enhance the induction of antiergotypic response when administered to patients. Taking into account that antiergotypic regulation acts on activated T cells independently of their antigenic specificity, immunotherapy utilizing autologous activated T lymphocytes can be of interest as a method for targeted action on pathogenetic components of atopic dermatitis.
About the authors
E. A. Blinova
Institute of Fundamental and Clinical Immunology
Author for correspondence.
Email: blinovaelena-85@yandex.ru
Russian Federation, Novosibirsk, 630099
E. A. Pashkina
Institute of Fundamental and Clinical Immunology
Email: blinovaelena-85@yandex.ru
Russian Federation, Novosibirsk, 630099
A. E. Tevs
Clinic of Immunopathology; Chair of Clinical Immunology
Email: blinovaelena-85@yandex.ru
Russian Federation, Novosibirsk, 630047; Novosibirsk, 630047
V. M. Nepomnyashchikh
Clinic of Immunopathology
Email: blinovaelena-85@yandex.ru
Russian Federation, Novosibirsk, 630047
M. I. Leonova
Clinic of Immunopathology
Email: blinovaelena-85@yandex.ru
Russian Federation, Novosibirsk, 630047
D. V. Demina
Clinic of Immunopathology
Email: blinovaelena-85@yandex.ru
Russian Federation, Novosibirsk, 630047
V. A. Kozlov
Institute of Fundamental and Clinical Immunology; Chair of Clinical Immunology
Email: blinovaelena-85@yandex.ru
Russian Federation, Novosibirsk, 630099; Novosibirsk, 630047